Humanized and chimeric N-terminal amyloid beta-antibodies
US6750324B1 · kind B1 · utility
108Cited by
79References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 28, 2000 |
| Grant date | Jun 15, 2004 |
| Priority date | — |
| Expiry date | Nov 28, 2020 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2821
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A&bgr; and antibodies binding to the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.